01:18 PM EST, 03/06/2024 (MT Newswires) -- (Updates with the latest stock movement in the headline and first paragraph.)

DexCom's ( DXCM ) shares were up more than 9% in recent Wednesday trading after the company's prescription-free glucose biosensor, Stelo by Dexcom ( DXCM ), won clearance from the US Food and Drug Administration on Tuesday.

Stelo, designed for individuals aged 18 and above who don't use insulin therapy, is a small, wearable sensor placed on the back of the upper arm to send real-time glucose information directly to the user's smartphone, DexCom ( DXCM ) said.

Stelo will be available to purchase online in the summer, DexCom ( DXCM ) said.

Price: 133.31, Change: +11.53, Percent Change: +9.47